Abstract
Background:
Chordomas are very rare low-grade malignant bone tumors that arise from the embryonic rests of the notochord. They are characterized by slow growth and long history with frequent local relapses, and sometimes metastases. While chemotherapy is not efficient, imatinib has shown antitumor activity.
Case presentation:
We report on a 76-year-old patient with EGFR-overexpressing advanced chordoma that progressed on imatinib and subsequently responded to erlotinib during 12 months.
Conclusions:
We report the fourth case of advanced chordoma treated with an EGFR inhibitor. We also review the literature concerning the rationale and potential of EGFR targeting in chordoma.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Benzamides
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / pathology
-
Chordoma / drug therapy*
-
Chordoma / pathology
-
ErbB Receptors / antagonists & inhibitors*
-
Erlotinib Hydrochloride
-
Humans
-
Imatinib Mesylate
-
Male
-
Molecular Targeted Therapy
-
Neoplasm Staging
-
Piperazines / administration & dosage
-
Piperazines / therapeutic use
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrimidines / administration & dosage
-
Pyrimidines / therapeutic use
-
Quinazolines / administration & dosage
-
Quinazolines / therapeutic use
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Quinazolines
-
Imatinib Mesylate
-
Erlotinib Hydrochloride
-
ErbB Receptors